Intuitive Surgical Delivers Record Da Vinci 5 Sales, Yet a Single Metric Keeps the Stock at 52-Week Lows
Published on 07/21/2026 at 17:33 | Redaktion boerse-global.de
Intuitive Surgical posted what many would call a textbook beat-and-raise quarter, yet its shares have been pinned near multi-year lows. The contradiction stems from a single, closely watched metric: the pace of da Vinci procedures in the United States, which slowed more sharply than the market anticipated.
After hitting a new 52-week trough of €299.60 in Frankfurt on Monday, the stock managed a modest recovery to €311.00 on Tuesday, a 0.32% uptick. The earlier plunge—14.1% in U.S. trading—was triggered by the company’s disclosure that domestic procedure growth decelerated from 13.5% in the first quarter to around 12% in the second. That undercut the consensus that had built around a faster clip, overshadowing a quarter in which Intuitive Surgical placed a record 468 da Vinci systems worldwide, more than half of which—246 units—were the newest da Vinci 5 model.
Operating strength obscured by home-market jitters
Total revenue for the second quarter of 2026 climbed 19% year-over-year to $2.89 billion, and adjusted earnings per share landed at $2.80, comfortably above analyst estimates. International procedures maintained a brisk 20% growth rate, and global procedure volumes across the da Vinci and Ion platforms expanded roughly 16% overall.
The da Vinci 5’s rapid adoption was a clear bright spot. U.S. placements alone rose 24% from a year earlier, propelled by hospitals upgrading to the latest generation. Yet the shift in the domestic procedure growth trajectory has become the primary lens through which investors view the company’s near-term outlook.
Should investors sell immediately? Or is it worth buying Intuitive Surgical?
Analyst targets get trimmed, conviction splits
The Wall Street analyst community responded with a flurry of price-target reductions, even though most maintained positive ratings on the stock. Bernstein SocGen Group cut its target from $750 to $685 while keeping an Outperform rating and raising its 2027 EPS estimate to $12.71. Stifel lowered its target to $550, and BMO Capital Markets held its Outperform rating but trimmed its target to $518. The consensus among covering analysts now sits at roughly $504.56, a figure that underscores the tension between long-term faith in the surgical-robotics story and short-term caution over the U.S. headwind.
BMO, however, took the view that the strong quarterly numbers demonstrate the company’s operational substance despite the headwinds in its home market. That dual reading—bullish on the business, cautious on the stock—has become the prevailing tone on the Street.
Extended-Use program adds a new layer of uncertainty
Adding to the debate is the company’s announcement of an Extended-Use program, scheduled to launch in the first half of 2027. The initiative would increase the permissible usage frequency of certain instruments, thereby lowering costs for hospitals. But because recurring revenue from instruments and service accounts for a significant chunk of Intuitive Surgical’s earnings, and the program’s pricing details remain undefined, it has introduced an element of ambiguity. Some analysts are still assessing whether the revenue impact will be more than offset by higher procedure volumes stimulated by the lower per-procedure cost.
Intuitive Surgical at a turning point? This analysis reveals what investors need to know now.
Valuation hits a five-year low as the chart signals oversold
After the correction, the stock’s price-to-earnings ratio has sunk to levels not seen in five years, according to market data. The Relative Strength Index stands near 34, a reading that many technicians interpret as oversold territory. Shares currently trade roughly 13% below their 50-day moving average of €358.27, and the year-to-date decline has reached 36.42%. From the January 2026 peak of €516.50, the drop exceeds 40%.
The combination of a depressed valuation and an RSI in the oversold zone may be providing the underpinning for the tentative stabilization around the psychologically important €300 mark. But the decisive factor for the rest of the year will likely be the next reading on U.S. procedure growth—whether it stays near 12%, rebounds toward earlier rates, or deteriorates further. Also hanging in the balance is how much of a drag the Extended-Use program will prove to be on the high-margin recurring revenue stream once its details become clear. For now, Intuitive Surgical’s operating engine is humming, but the throttle in its most important market has investors watching the gauges more closely than ever.
Ad
Intuitive Surgical Stock: New Analysis - 21 July
Fresh Intuitive Surgical information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
